Navigation Links
Isis Reports Interim Phase 2 Data on ISIS-APOCIII Rx as a Single Agent in Patients With Very High to Severely High Triglycerides
Date:8/31/2013

e potential to fill this need."

The monotherapy portion of the ongoing Phase 2 study of ISIS-APOCIIIRx is a double-blind, randomized, placebo-controlled 13-week study designed to assess the safety and activity of ISIS-APOCIIIRx in patients with very high to severely high triglyceride levels (between 440 and 2,000 mg/dL).  The data reported today is an interim analysis of 28 patients who completed 13 weeks of treatment with ISIS-APOCIIIRx or placebo.  In this study, patients treated with ISIS-APOCIIIRx experienced dose-dependent, robust and prolonged, mean percent reductions from baseline in apoC-III, triglycerides and apoC-III-associated VLDL particles.  Furthermore, these patients demonstrated a rapid, prolonged and statistically significant mean percent increase from baseline in HDL-C.Table 1:  ISIS-APOCIIIRx Produced Statistically Significant Reductions of Triglycerides, ApoC-III and ApoC-III-associated VLDL as a Single Agent in a Phase 2 Study in Patients with Very High to Severely High Triglyceride Levels.  Mean % Changes From Baseline at Primary Endpoint.*Placebo 

(n=9)

ISIS-APOCIIIRx

100 mg  (n=9)

ISIS-APOCIIIRx

200 mg  (n=5)

ISIS-APOCIIIRx

 300 mg
(n=5)ApoC-III

+5%

-43%

(p=0.04)

 -72%

(p=0.004)

 -79%

(p=0.003)Triglycerides

+26%

-31%

(p=0.08)

-65%

(p=0.02)

-75%

(p=0.004)ApoC-III VLDL

+19%

-27%

(p=0.17)

 -73%

(p=0.003)

 -89%

(p=0.004)HDL-C

+3%

+30%

(p=0.08)

 +51%

(p=0.002)

 +57%

(p=0.001)non-HDL

+17%

-8%

(p=0.16)

-5%

(p=0.36)

-39%

(p=0.007)P value = vs
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. MGC Diagnostics Corporation Reports 2013 Third Quarter Operating Results
2. China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2013 Financial Results
3. Kewaunee Scientific Reports Record Sales and Earnings for First Quarter
4. China Orthopedic Devices Market, Contract Manufacturing in Orthopedic Industry Reports
5. Cancer Diagnostics Market: Sales Forecasts, 2013 Shares & Competitive Strategies Research Reports
6. VirtualScopics Reports Dr. Mostafa Analoui Elected Chairman of the Board
7. China Jo-Jo Drugstores, Inc. Reports Fiscal Year 2014 First Quarter Earnings Results and Schedules Conference Call for August 19, 2013
8. Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue and Earnings
9. ULURU Inc. Reports Second Quarter 2013 Financial Results
10. Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
11. CorMedix Reports Second Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 30, ... Guidance   ... including Core Earnings and ... Highlights of Q1 results  ... Underlying core earnings and underlying core EPS were flat, year-to-year , ...
(Date:7/29/2015)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today ... Test v2 for Premarket Approval (PMA) to the ... companion diagnostic test for AZD9291, an AstraZeneca investigational ... an acquired resistant mutation.  Patients ... with tumor containing an EGFR sensitizing mutation show ...
(Date:7/29/2015)...  Astellas today announced topline results from the ... safety of intravenous (IV) and oral isavuconazole, commercially ... adults with candidemia and other invasive Candida ... the trial did not meet its primary endpoint ... patients at the end of IV therapy compared ...
Breaking Medicine Technology:Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 2Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 3Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 4Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 5Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 2Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5
... , CAMBRIDGE, Mass. , May 11 The DNA ... Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation.  The ... Eugene Y. Chan , M.D. titled "Optomagnetic Finger Scanner for Malaria." , ... Dr. Chan,s project is one ...
... May 10 CrystalGenomics, Inc., a novel drug R&D ... study for its novel antibiotic candidate, CG400549, has been successfully completed ... , , ... (Enoyl-acyl carrier protein reductase, which is a critical enzyme in generating ...
Cached Medicine Technology:DNA Medicine Institute Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 2DNA Medicine Institute Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 3CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate 2
(Date:7/29/2015)... ... July 29, 2015 , ... VideoLink , ... Medical Center, located in New York, NY, selected the ReadyCam on-site video studio ... and scientists to immediately access worldwide TV and cable news networks and participate ...
(Date:7/29/2015)... ... July 29, 2015 , ... The federal ... impact drinking and substance abuse is having on lost productivity, workplace accidents and ... the billions per year. [1] Will Wesch, Director of Admissions for Novus ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... Our Best Shot: Expanding Prevention through Vaccination in Older Adults, that provides a ... recommendations on how industry, government, and health care experts can improve patient compliance. ...
(Date:7/29/2015)... ... July 29, 2015 , ... Potomac Pilates, an elite Washington, D.C. metro ... Rock the Reformer ® by Potomac Pilates. On Thursday, July 30, Potomac Pilates ... Reformer ® by Potomac Pilates will continue to offer the same classes and personal ...
(Date:7/29/2015)... ... 2015 , ... The report “Atherosclerosis - Pipeline Review, H1 ... slow, progressive disease that may start in childhood. The report strengthens R&D pipelines ... report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread ...
Breaking Medicine News(10 mins):Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 2Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 3Health News:Workplace Trouble: Survey Reveals Sharp Escalation in Restaurant/Food Service Employee Drug Abuse 2Health News:Workplace Trouble: Survey Reveals Sharp Escalation in Restaurant/Food Service Employee Drug Abuse 3Health News:Vaccination Rates in Older Adults Fall Short of Targets 2Health News:Vaccination Rates in Older Adults Fall Short of Targets 3Health News:Same Great Pilates Studio, New Brand - Rock the Reformer 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4